Decrease in serum thyroxine level by phenobarbital in rats is not necessarily dependent on increase in hepatic UDP-glucuronosyltransferase.
We have previously reported that there is a poor correlation between increase in the levels of UDP-glucuronosyltransferases, UGT1A1 and UGT1A6, and decrease in the levels of serum total thyroxine (T4) and free T4 in phenobarbital (PB)-treated rats, although the PB-induced decrease in rats is generally thought to occur through induction of the UDP-glucuronosyltransferase (T4-UDP-GT: UGT1A1 and UGT1A6). In the present study, to clarify a relationship between the decrease in serum T4 level and the increase in the T4-UDP-GT activity by PB in rats, we examined the relationship using Gunn rats, a mutant strain of Wistar rats deficient in UGT1A isoforms. Levels of serum total T4, free T4, and total triiodothyronine (T3) were markedly decreased not only in Wistar rats but also in Gunn rats 1 day after the final administration of PB (80 mg/kg i.p., once daily for 4 days), and no significant difference in magnitude of the decrease between Wistar and Gunn rats was observed. On the other hand, the level and activity of T4-UDP-GT were significantly increased by treatment with PB in Wistar rats but not in Gunn rats. Furthermore, significant decrease in the activity of hepatic type I iodothyronine deiodinase, which mediates the deiodination of T4 and T3, by PB treatment was observed in both Wistar and Gunn rats. In addition, no significant change in the level of serum thyroid-stimulating hormone, the activity of hepatic sulfotransferase, and the binding of [125I]T4 to serum transthyretin and albumin by PB treatment was observed in either Wistar or Gunn rats. In conclusion, the present results demonstrate that the decrease in serum total T4 level by PB in Gunn rats is not dependent on the increase in hepatic T4-UDP-GT activity and suggest that even in Wistar rats, the PB-induced decrease in serum T4 level does not occur only through increase in hepatic T4-UDP-GT.
Kato
Yoshihisa
Y
School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan. kato@ys7.u-shizuoka-ken.ac.jp
Suzuki
Hiroshi
H
Ikushiro
Shinichi
S
Yamada
Shizuo
S
Degawa
Masakuni
M
D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage / Q000494:pharmacology*; D004790:Enzyme Induction; D014453:Glucuronosyltransferase / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D007453:Iodide Peroxidase / Q000378:metabolism; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D010634:Phenobarbital / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011911:Rats, Gunn; D017208:Rats, Wistar; D013974:Thyroxine / Q000097:blood*; D014284:Triiodothyronine / Q000097:blood; D000099148:UGT1A1 Enzyme
D000927:Anticonvulsants; D014453:Glucuronosyltransferase; D007453:Iodide Peroxidase; D010634:Phenobarbital; D013974:Thyroxine; D014284:Triiodothyronine; D000099148:UGT1A1 Enzyme; C109812:iodothyronine deiodinase type I; C107611:UDP-glucuronosyltransferase, UGT1A7